Fount Bio closes Series A financing led by Morningside Ventures to advance Flī-HA platform technology to clinical proof of concept.
Fount Bio, Inc. successfully closed a Series A round of financing led by Morningside Ventures. This initial investment will be focused on progressing Fount Bio’s, Flī-HA (functional ligand hyaluronic acid) technology forward into clinical evaluation for aesthetic and dermatological indications. Anthony Aiudi and Justin Burns from Morningside Ventures will be ...
